Corindus Vascular Robotics Inc (NYSEMKT:CVRS) has been given a $3.00 target price by analysts at Cowen and Company in a report released on Wednesday. The firm presently has a “buy” rating on the medical equipment provider’s stock. Cowen and Company’s price target suggests a potential upside of 80.72% from the company’s current price.

A number of other research firms have also recently commented on CVRS. ValuEngine cut shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. B. Riley reissued a “buy” rating and set a $3.00 target price on shares of Corindus Vascular Robotics in a research report on Monday, May 15th. Zacks Investment Research raised shares of Corindus Vascular Robotics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, July 11th. Finally, BidaskClub cut shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $2.67.

Shares of Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 1.66 on Wednesday. The stock’s market capitalization is $310.55 million. Corindus Vascular Robotics has a 12 month low of $0.40 and a 12 month high of $2.25. The firm has a 50 day moving average of $1.79 and a 200-day moving average of $1.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Corindus Vascular Robotics had a negative net margin of 1,272.20% and a negative return on equity of 181.63%. The business had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $3.10 million. Analysts forecast that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cowen and Company Analysts Give Corindus Vascular Robotics Inc (CVRS) a $3.00 Price Target” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/10/cowen-and-company-analysts-give-corindus-vascular-robotics-inc-cvrs-a-3-00-price-target.html.

Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in Corindus Vascular Robotics by 73.3% in the first quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock valued at $882,000 after buying an additional 284,855 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Corindus Vascular Robotics by 240.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 201,900 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Corindus Vascular Robotics by 40.7% in the second quarter. Bank of New York Mellon Corp now owns 229,380 shares of the medical equipment provider’s stock valued at $426,000 after buying an additional 66,368 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 32,608 shares during the last quarter.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Stock Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related stocks with our FREE daily email newsletter.